TLP
Tri Locum Partners Portfolio holdings
AUM
$330M
This Quarter Return
-2.32%
1 Year Return
+35.44%
3 Year Return
+388.28%
5 Year Return
–
10 Year Return
–
AUM
$243M
AUM Growth
+$243M
(-5.1%)
Cap. Flow
+$6.2M
Cap. Flow
% of AUM
2.55%
Top 10 Holdings %
Top 10 Hldgs %
62.43%
Holding
66
New
29
Increased
14
Reduced
7
Closed
16
Top Buys
| 1 |
argenx
ARGX
|
$17.8M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
$11.6M |
| 3 |
Eli Lilly
LLY
|
$9.1M |
| 4 |
Guardant Health
GH
|
$7.76M |
| 5 |
Stevanato
STVN
|
$7.47M |
Top Sells
| 1 |
Protagonist Therapeutics
PTGX
|
$18.2M |
| 2 |
Regeneron Pharmaceuticals
REGN
|
$15M |
| 3 |
Jazz Pharmaceuticals
JAZZ
|
$11.4M |
| 4 |
INBX
Inhibrx, Inc. Common Stock
INBX
|
$9.06M |
| 5 |
Bristol-Myers Squibb
BMY
|
$8.97M |
Sector Composition
| 1 | Healthcare | 89.29% |
| 2 | Consumer Staples | 4.85% |
| 3 | Industrials | 0.1% |
| 4 | Real Estate | 0.04% |
| 5 | Materials | 0.04% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
argenx
ARGX
$43.6B
| $31.3M | 12.84% | 82,735 +46,855 | +131% | +$17.8M |
|
|
2
Eli Lilly
LLY
$657B
| $22.6M | 9.25% | 69,667 +28,057 | +67% | +$9.1M |
|
3
Edwards Lifesciences
EW
$47.8B
| $17.4M | 7.11% | 182,654 +75,864 | +71% | +$7.21M |
|
|
4
Stevanato
STVN
$6.28B
| $14.1M | 5.76% | 889,496 +472,576 | +113% | +$7.47M |
|
|
CCXI
5
DELISTED
ChemoCentryx, Inc.
CCXI
| $13.5M | 5.54% | 545,532 +249,205 | +84% | +$6.18M |
|
6
The Beauty Health Co
SKIN
$264M
| $11.8M | 4.81% | 914,194 +420,893 | +85% | +$5.41M |
|
|
CTLT
7
DELISTED
CATALENT, INC.
CTLT
| $11.6M | 4.76% | +108,241 | New | +$11.6M |
|
|
BLU
8
DELISTED
BELLUS Health Inc.
BLU
| $10.5M | 4.29% | 1,134,408 +124,793 | +12% | +$1.15M |
|
9
Evolent Health
EVH
$1.12B
| $9.98M | 4.09% | 324,869 +93,370 | +40% | +$2.87M |
|
|
RXDX
10
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $8.97M | 3.67% | 317,758 +168,692 | +113% | +$4.76M |
|
|
11
Jazz Pharmaceuticals
JAZZ
$7.75B
| $8.95M | 3.66% | 57,363 -73,315 | -56% | -$11.4M |
|
|
12
Guardant Health
GH
$8.41B
| $7.76M | 3.18% | +192,308 | New | +$7.76M |
|
|
TCDA
13
DELISTED
Tricida, Inc. Common Stock
TCDA
| $7.08M | 2.9% | 731,142 +301,759 | +70% | +$2.92M |
|
14
Altimmune
ALT
$338M
| $6.72M | 2.75% | +574,646 | New | +$6.72M |
|
|
ITCI
15
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $6.37M | 2.61% | +111,572 | New | +$6.37M |
|
16
BioNTech
BNTX
$24B
| $5.91M | 2.42% | 39,663 +8,740 | +28% | +$1.3M |
|
17
Inspire Medical Systems
INSP
$2.77B
| $5.79M | 2.37% | +31,705 | New | +$5.79M |
|
|
HZNP
18
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
| $5.48M | 2.25% | 68,750 -63,582 | -48% | -$5.07M |
|
19
Xenon Pharmaceuticals
XENE
$2.98B
| $5.06M | 2.07% | +166,399 | New | +$5.06M |
|
20
Kezar Life Sciences
KZR
$28.9M
| $4.17M | 1.71% | 504,342 -226,555 | -31% | -$1.87M |
|
21
Travere Therapeutics
TVTX
$1.56B
| $3.93M | 1.61% | +162,014 | New | +$3.93M |
|
22
Celldex Therapeutics
CLDX
$1.47B
| $3.56M | 1.46% | 132,148 -251,171 | -66% | -$6.77M |
|
23
Allogene Therapeutics
ALLO
$251M
| $3.1M | 1.27% | +272,123 | New | +$3.1M |
|
24
Revolution Medicines
RVMD
$7.1B
| $2.89M | 1.18% | 148,453 -22,002 | -13% | -$429K |
|
25
Coherus Oncology, Inc. Common Stock
CHRS
$135M
| $2.73M | 1.12% | +376,486 | New | +$2.73M |
|